25iP-NBOMe

From WikiMD's WELLNESSPEDIA


Chemical structure of 25iP-NBOMe

25iP-NBOMe is a synthetic psychedelic compound belonging to the NBOMe class. It is a derivative of the phenethylamine 2C-iP and is known for its potent hallucinogenic effects. The compound is part of a larger group of substances that have been explored for their psychoactive properties.

Chemical Structure and Properties[edit]

25iP-NBOMe is chemically related to other NBOMe compounds, such as 25I-NBOMe and 25C-NBOMe. The structure of 25iP-NBOMe includes a methoxybenzyl group attached to the nitrogen of the phenethylamine backbone, which is characteristic of the NBOMe series. This modification significantly increases the compound's affinity for the 5-HT2A receptor, which is primarily responsible for its psychedelic effects.

Pharmacology[edit]

The primary mechanism of action for 25iP-NBOMe is its agonism of the 5-HT2A receptor, a subtype of the serotonin receptor. This interaction is believed to be responsible for the hallucinogenic effects experienced by users. The compound may also interact with other serotonin receptor subtypes, contributing to its overall pharmacological profile.

Effects[edit]

Users of 25iP-NBOMe report a range of effects, including visual and auditory hallucinations, altered perception of time, and changes in mood and cognition. The intensity and duration of these effects can vary depending on the dose and individual sensitivity. As with other NBOMe compounds, there is a risk of adverse effects, particularly at higher doses.

Safety and Legal Status[edit]

The safety profile of 25iP-NBOMe is not well-established, and there have been reports of severe adverse reactions, including vasoconstriction, tachycardia, and seizures. Due to these risks, the compound is often classified as a research chemical and is not approved for human consumption in many jurisdictions. The legal status of 25iP-NBOMe varies by country, with some places having specific bans on NBOMe compounds.

Related Compounds[edit]

Related Pages[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=25iP-NBOMe&oldid=6622487"